RiverVest is a leading venture capital firm building life science companies
to address significant unmet needs of patients and deliver consistently strong returns to investors.
/ RIVERVEST NEWS
Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG – 4/2/2026
Avalyn Announces Publication Demonstrating Correlation Between Imaging, Improved Lung Function, and Quality of Life with AP01 in Patients with Idiopathic Pulmonary Fibrosis – 3/25/2026
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis – 3/23/2026
Sparrow Appoints Biopharmaceuticals Industry Veteran, Carlo Incerti, M.D. to its Board of Directors – 2/2/2026
Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease – 1/26/2026
U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia/T Cell Lymphoblastic Lymphoma – 1/21/2026
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates – 1/8/2026
Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluating Clofutriben for Difficult-to-Control Type 2 Diabetes – 1/6/2026
Subscribe to our newsletter